Hidden epidemic of macrolide-resistant pneumococci
- PMID: 15963272
- PMCID: PMC3367596
- DOI: 10.3201/eid1106.050147
Hidden epidemic of macrolide-resistant pneumococci
Abstract
Community-acquired respiratory tract infections (RTIs) account for a substantial proportion of outpatient antimicrobial drug prescriptions worldwide. Concern over the emergence of multidrug resistance in pneumococci has largely been focused on penicillin-resistant Streptococcus pneumoniae. Macrolide antimicrobial drugs have been widely used to empirically treat community-acquired RTIs because of their efficacy in treating both common and atypical respiratory pathogens, including S. pneumoniae. However, increased macrolide use has been associated with a global increase in pneumococcal resistance, which is leading to concern over the continued clinical efficacy of the macrolides to treat community-acquired RTIs. We provide an overview of macrolide-resistant S. pneumoniae and assess the impact of this resistance on the empiric treatment of community-acquired RTIs.
References
-
- World Health Organization. The World health report 2004 — changing history [monograph on the Internet]. 2004. [cited 2005 Apr 1]. Available from http://www.who.int/whr/2004/en/report04_en.pdf
-
- Hall MJ, DeFrances CJ. National hospital discharge survey. Adv Data. 2002;332:1–18. - PubMed
-
- Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med. 2004;117(Suppl 3A):38–15S. - PubMed
-
- Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J. 2002;36(Suppl):36:3–8s. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical